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ABSTRACT 
Objective: To test whether cerebrospinal fluid (CSF) neurofilament light (NFL) levels predict 
hippocampal atrophy rate in cognitively healthy older adults independently of the established 
CSF Alzheimer’s disease (AD) biomarkers.  
Methods:  Older adults undergoing elective surgery in spinal anesthesia were included in a 
prospective cohort study. At baseline, participants underwent comprehensive cognitive testing 
and brain magnetic resonance imaging (MRI), in addition to CSF sampling in conjunction with 
anesthesia.  At two-year follow-up, the cognitive testing and MRI were repeated. 144 cognitively 
healthy participants with CSF biomarker samples and/or brain MRI were included. Of these, 88 
had MRI at both time points and CSF NFL measures.  
Results: CSF NFL levels predicted hippocampal atrophy rate independently of age, CSF β-
amyloid 1-42 and phosphorylated tau (P-tau) levels. Including NFL, P-tau and age in the same 
linear regression model, higher NFL levels and lower P-tau levels predicted significantly higher 
hippocampal atrophy rate (full model adjusted R2=.20, NFL β=-.34, P-tau β=.27). The results 
were upheld in a subgroup of participants with very low AD risk based on genetic, cognitive and 
biomarker information. 
Conclusion: CSF NFL predicts neurodegeneration in older adults with very low probability of 
AD. The present results suggest that factors previously shown to be important for brain 
degeneration in mild cognitive impairment may also impact brain changes in normal aging, 
demonstrating that NFL is likely to be a marker of AD-independent, age-expected 
neurodegeneration.  
 
INTRODUCTION 
Hippocampal atrophy rates are higher in patients with Alzheimer’s disease (AD) than in 
cognitively healthy older adults.1 However, hippocampal atrophy is known to accelerate from 
midlife onwards also in persons with low AD-risk,2 and hippocampus is one of the brain areas 
with highest atrophy rate in aging,2 reported to be around 1% annually.2, 3 Thus, identification of 
biomarkers predicting hippocampal atrophy is critical for understanding brain changes both in 
normal aging and early AD. Interestingly, a recent study showed that cerebrospinal fluid (CSF) 
neurofilament light subunit (NFL) levels predicted hippocampal atrophy in mild cognitive 
impairment (MCI) patients,4 indicating that CSF NFL could be a progression marker in AD.  
 
Neurofilaments are important cytoskeletal components of neuronal axons, and CSF NFL levels 
are believed to reflect axonal degeneration.5, 6 CSF NFL levels are associated with age,7-9 white 
matter lesions,10 AD,4, 9, 11 and other neurodegenerative diseases.9, 11-14 Previous studies have 
indicated a relationship between high CSF NFL and lower brain volume in frontotemporal lobe 
dementia,15 and non-demented older adults,8, 16 but studies are mostly cross-sectional and results 
have not been consistent.17, 18 The relationship between CSF NFL levels and hippocampal 
atrophy in cognitively healthy older adults has never been tested, but is critical for understanding 
whether NFL is a general or disease-specific atrophy marker. Thus, the objective of this study 
was to test whether CSF NFL levels predict hippocampal atrophy rate in cognitively healthy 
older adults independently of the established CSF AD biomarkers β-amyloid 1-42 (Aβ42) and 
phosphorylated tau (P-tau).19 
 
METHODS 
Participants 
We recruited patients scheduled for elective surgery in spinal anesthesia turning 65 years or older 
the year of inclusion. Dementia, previous stroke with sequela, Parkinson’s disease and other 
neurodegenerative diseases likely to affect cognition were exclusion criteria. The participants 
were assessed with a multi-domain battery of cognitive tests before surgery, comprising the Mini 
Mental Status Examination (MMSE),20 Clock Drawing Test,21 Word List Memory Task,22 Trail 
Making Test A and B,23 Kendrick Object Learning Test,24 and verbal fluency (FAS test and 
Animal Naming),25 giving 11 test scores. Blood and CSF samples were collected by the 
anesthesiologist in conjunction with spinal anesthesia, and the participants underwent magnetic 
resonance imaging (MRI) after surgery. The mean time between CSF sampling and MRI at 
baseline was 8 weeks (standard deviation [SD] [range]: 6 [-20 to 24]). Participants underwent a 
second MRI and were tested with the same battery of cognitive tests at two-year follow-up 
(mean time between MRIs 2.2 years, SD [range]: 0.3, [1.6 to 2.9]) (see table 1).     
 
[Insert table 1 around here] 
 
We selected participants as shown in figure e-1. Only participants with CSF biomarker analyses 
and/or brain MRI(s) were included. We selected only cognitively healthy participants based on 
the following procedure: First, participants offered referral to cognitive assessment were 
excluded. Next, we included all participants with MMSE score ≥ 27. Last, for participants with 
MMSE score < 27, only those with none or one other abnormal test score(s) when last tested 
were included. Abnormal score was defined as more than 1.5 SD below the mean normal value 
for age, sex, and educational level. 4 participants with CSF NFL levels > 4000 pg/mL were 
excluded (CSF NFL levels were more than ± 3 SD from the mean value). From this remaining 
sample, we selected two separate groups for subgroup analyses: 1) we excluded participants with 
additional conditions that could possibly affect hippocampal atrophy (details table e-1) 2) we 
selected participants with very low risk of AD fulfilling all the three following criteria: 1) Aβ42 
> 550 pg/mL26 2) no apolipoprotein E (APOE) 4 alleles 3) stable or improved delayed recall 
score on Word List Memory Task at two-year follow-up compared to baseline.  
 
Standard protocol approvals, registrations, and patient consents 
The study was conducted in accordance with the Declaration of Helsinki, and was approved by 
the Regional Committee for Ethics in Medical Research in Norway (REK 2011/2052). All 
participants provided written informed consent. 
 
Magnetic Resonance Imaging acquisition and processing 
T1-weighted MPRAGE 3D images were acquired with a 1.5 T Siemens Avanto scanner using a 
12-channel head coil (TR=2400 ms, TE=3.79ms, Field of View=240mm, slice 
thickness=1.20mm, pixel size=1.25x1.25mm). 
 
The scans were processed with FreeSurfer (version 5.3) and its specific longitudinal stream 
(https://surfer.nmr.mgh.harvard.edu). For each MRI, the standard Freesurfer pipeline performs a 
set of automated procedures for the cortical reconstruction and volumetric segmentation of the 
individual scans, documented elsewhere.27, 28 We used hippocampi volume measures and white 
matter hypointensities (WM-hypointensities) estimations obtained from a segmentation based on 
both a subject-independent probabilistic atlas and subject-specific intensity measures. In addition, 
it is important to note that the Freesurfer longitudinal stream includes a set of methods designed 
to minimize the bias to any time point in a participant and which are shown to lead to increased 
statistical power, better separation of groups based on atrophy, and higher reproducibility. These 
methods include the generation of a subject-specific intermediate template followed by a 
projection of each time point to this template.29, 30  
 
APOE genotyping 
Blood samples were genotyped for APOE (gene map locus 19q13.2) using TaqMan Allelic 
Discrimination technology (Applied Biosystems, Carlsbad, CA, USA). Genotypes were obtained 
for the two SNPs that are used to unambiguously define the ε2, ε3, and ε4 alleles (rs7412 and 
rs429358).  
 
CSF collection and analyses 
CSF was collected in polypropylene tubes, centrifuged at room temperature for 10 minutes, the 
supernatant aliquoted into polypropylene tubes, and frozen at -80 °C pending analyses. Mean 
time from CSF sampling to freezing was 85 minutes (SD, [range]: 22, [16 to 127]).  Samples 
were sent on dry ice to the Clinical Neurochemistry Laboratory at Sahlgrenska University 
Hospital, Mölndal, Sweden, for analyses. CSF Aβ42, total tau (T-tau) and P-tau concentrations 
were determined using INNOTEST enzyme-linked immunosorbent assays (Fujirebio, Ghent, 
Belgium) and CSF NFL concentrations using a commercial ELISA (UmanDiagnostics, Umeå, 
Sweden). Analyses were performed by board-certified laboratory technicians masked to clinical 
data. Intra-assay coefficients of variation were 9-13% and the lower limit of detection for NFL 
was 50 pg/mL. We found a strong correlation between CSF T-tau and P-tau levels (r=.96, 
p<.001), thus we only used CSF P-tau in statistical analyses.  
 
Statistical analysis 
We calculated hippocampal atrophy rate as the annual percent change in hippocampal volume 
(average of both hemispheres), normalized by the average volume across time points and divided 
by years between scans. We also calculated the average WM-hypointensities volume across time 
points for use as a control variable.  
 
We tested associations between CSF biomarkers, age and hippocampal atrophy rate using SPSS 
(version 22). Generalized Additive Mixed Models (GAMM) implemented in R (www.r-
project.org) using the package “mgcv”31 was used to derive the age-function for hippocampal 
atrophy and for the relationship between hippocampal change and CSF NFL levels, taking 
advantage of all longitudinal and cross-sectional observations, run through the PING data portal 
(http://pingstudy.ucsd.edu/welcome.html ).32 Akaike Information Criterion (AIC) 33 was used to 
guide model selection and help guard against over-fitting. For analyses including CSF 
biomarkers and not MRI measures, we used age at the day of CSF sampling. For analyses 
including MRI measures, we used the age at the day of baseline MRI.  
 
We tested correlations between CSF biomarkers, age and hippocampal atrophy rate using 
Pearson correlations, and hippocampal volume change using paired samples T-test. We 
performed multiple linear regression analyses to test associations between age, CSF biomarkers 
and hippocampal atrophy rate. The regressions were performed in several steps. The first model 
included NFL and age as predictors of hippocampal atrophy rate. Next, we tested the predictive 
power of Aβ42 and P-tau levels separately in conjunction with NFL in the model. The resulting 
regression model was tested for stability by including sex and WM-hypointensities separately. 
We also tested the final regression model within two low risk subgroups: 1) the group without 
additional conditions and 2) the very low AD risk subgroup. Sensitivity analyses were performed 
with and without outliers (defined as studentized residuals > ± 2) for all regression models. 
Finally, we ran mediation analyses using the SPSS macro INDIRECT.34 Mediation is present if 
the relationship between the predictor variable and the dependent variable (c) attenuates when 
accounting for a third variable (the mediator) (c’). The % reduction was calculated as (c-c’)/c. 
The significance of the indirect effect (a*b) was tested using bootstrapped confidence intervals 
(CI). Standardized coefficients were obtained using z-scores.  
 
RESULTS  
CSF biomarkers, hippocampal volume and demographic factors 
Demographics, and CSF biomarker and MRI characteristics are shown in table 1. NFL levels 
correlated positively with age (r=.41, p<.001). P-tau levels also correlated positively with age 
(r=.21 p=.02), whereas Aβ42 levels did not correlate with age (r=-.002, p=.98). High NFL levels 
correlated with high P-tau levels (r=.28, p=.001), but not with Aβ42 levels (r=.02, p=.85).  
 
CSF NFL levels and hippocampal atrophy rate 
Hippocampal atrophy was significant (mean [SD], range: -45.38 mm3 [75.35], -30.43 to -60.34, 
t=6.02, p<.001), and the mean annual atrophy rate was -0.61% (n=100). Age correlated with 
higher atrophy rate (r=-.29, p=.003), indicating accelerated atrophy with increasing age. This 
relationship was confirmed with GAMM for the full sample, as illustrated in figure 1. We ran a 
multiple regression analysis using NFL and age as predictors of hippocampal atrophy rate. 
Higher NFL levels predicted higher hippocampal atrophy rate (p = .02) (see table 2). Age was 
not a significant predictor in this model. In the next step, Aβ42 level was also introduced as a 
possible predictor, and did not predict hippocampal atrophy rate independently of NFL, while 
NFL was still significant (table 2). The last step included P-tau as a predictor together with age 
and NFL, and we obtained a model with higher NFL levels and lower P-tau levels predicting 
higher hippocampal atrophy rate (table 2) independently of age. Regression analyses results were 
unchanged when excluding 5-6 outliers per analysis.  
  
The relationship between NFL and hippocampal volume was also tested with GAMM to take 
advantage of all data points, obtaining an optimal fit based on both cross-sectional and 
longitudinal information. The sample was divided into NFL+ and NFL- by a median split, and 
the relationship between hippocampal volume and age was plotted in each group, with sex as a 
covariate. AIC for the model was 2587 and NFL status yielded a highly significant contribution 
(t =-2.96, p < .005). Removing NFL increased AIC to 2595, indicating a worse fit. Adding P-tau 
as a covariate did not improve the model fit (AIC = 2588), and P-tau did not contribute 
significantly (t = -0.18, p = 0.85) while NFL still did (t = -2.66, p < .01). Thus, the initial model 
was preferred and plotted in figure 2. 
 
[Insert table 2, figure 1 and figure 2 around here] 
 
Adjusting for effect of white matter hypointensities and sex on hippocampal atrophy rate 
Since vascular brain pathology may affect the relationship between NFL and hippocampal 
atrophy rates,10 we entered WM-hypointensities into the regression model including age, NFL 
and P-tau levels as predictors of hippocampal atrophy rate. NFL and P-tau levels were still 
significant predictors of hippocampal atrophy rate, whereas WM-hypointensities did not predict 
hippocampal atrophy rate (data not shown). Results were unchanged after exclusion of 6 outliers. 
We adjusted for sex in the same way as for WM-hypointensities. Also in this model, NFL and P-
tau levels were the only significant predictors of hippocampal atrophy rate (data not shown). Sex 
was not a significant predictor, however after exclusion of 6 outliers, sex was also a significant 
predictor (higher atrophy rates in males).  
 CSF NFL levels and hippocampal atrophy in low risk subgroups 
We further applied our final regression model including age, NFL, and P-tau levels as predictors 
of hippocampal atrophy rate in two low risk subgroups: 1) in the subgroup without additional 
conditions, NFL was the only significant predictor (table e-2). However, when excluding 5 
outliers, P-tau was also a significant predictor as in the full sample. 2) in the subgroup of Aβ42 
negative participants without APOE4 alleles, and stable memory function between baseline and 
follow up, higher NFL levels and lower P-tau levels predicted higher hippocampal atrophy rate 
independent of age as in the full sample (table e-3). The results were unchanged when increasing 
the Aβ42 cutoff from 550 to 650 pg/mL, and also when excluding 2-3 outliers per analysis. 
 
Mediation analyses 
We tested the mediating (indirect) effect of NFL on the relationship between age and 
hippocampal atrophy rate (figure 3). NFL was a significant mediator, with bootstrapped 95 % 
confidence interval of -.24 to -.01, and accounted for 36 % of the age effect on hippocampal 
atrophy rate. In our model, the total effect of age on hippocampal atrophy was β=- .23 equal to 
the sum of the direct effect of age (β=-.15) and the indirect effect through the relationship with 
NFL (β=-.08).  
 
 [Insert figure 3 around here] 
 DISCUSSION  
High CSF NFL levels predicted higher hippocampal atrophy rate in cognitively healthy older 
adults. While previous studies have demonstrated this in samples of high-risk participants, i.e. 
MCI patients,4 here we show that the relationship was replicated in a sample with very low AD-
risk, and that NFL predicted hippocampal atrophy independently of the established AD CSF 
biomarkers Aβ42 and P-tau. This suggests that CSF NFL may be an important marker of 
neurodegeneration both in normal aging and in age-related neurodegenerative diseases.  
 
The only previous study assessing CSF NFL in relation to longitudinal volume change in older 
adults found that higher NFL levels were associated with deterioration in whole-brain, 
ventricular and hippocampal volume in MCI patients.4 However, cross-sectional studies in non-
demented adults have been more inconsistent. One study found that high CSF NFL correlated 
with ventricular size, but not with sulcal atrophy,16 a second study found a correlation between 
brain parenchymal fraction and CSF NFL that did not survive adjustment for age,8 while a third 
study found no relationship between baseline CSF NFL levels and gray matter volumes 3.5 years 
later.18 In frontotemporal dementia, higher CSF NFL is associated with lower gray and white 
matter volumes, including in the temporal lobe,15 while findings in multiple sclerosis (MS) and 
related disorders are less straightforward.17, 35 Thus, previous literature on the association 
between CSF NFL and brain volumes is scarce and inconsistent, but the only longitudinal study 
in older adults is in line with our findings,4 showing that high CSF NFL predicts more 
hippocampal atrophy in MCI patients. The present study takes these results further by showing 
that the NFL-atrophy association is likely not caused by AD-specific mechanisms, but is 
important also in AD-independent, age-expected hippocampal decline. 
 
Neurofilaments are abundant in neuronal axons where they are essential for axon radial growth,5 
but are also found in soma and dendrites of neurons.36 NFL is expressed in neurons in both the 
central and the peripheral nervous system,36 including the hippocampus.37 Thus, when a neuron 
is damaged, NFL is believed be released into the extracellular compartment resulting in 
increased CSF NFL levels.5 Age is associated with increasing CSF NFL levels in several 
studies,7-9, 12, 17 suggesting that CSF NFL levels increase with normal aging. Interestingly, we 
found that NFL levels could explain more than one third of the age-related increase in 
hippocampal atrophy rates. As accelerated decline of the hippocampus also in normal aging is 
observed independently of AD-related pathology,2 this is an important finding.  Thus, our results 
indicate that CSF NFL levels reflect processes characterizing normal aging.  
 
There has recently been increasing focus on amyloid-independent neurodegeneration in aging, 
often referred to as suspected non-Alzheimer pathology (SNAP), making it important to map out 
correlates of atrophy also in AD-typical areas in Aβ42 negative older adults.38 Thus, we created a 
subgroup with very low AD risk (only Aβ42 negative participants), in which our finding was 
upheld. This bolsters that AD brain pathology is not a confounder of the relationship between 
CSF NFL and hippocampal atrophy rate, and suggests that CSF NFL most likely reflects 
neurodegeneration processes in normal aging. Further, in another subgroup analysis, CSF NFL 
predicted hippocampal atrophy rate after exclusion of participants with additional risk conditions, 
supporting that CSF NFL likely reflects normal aging processes. Previous studies suggest that 
CSF NFL may reflect the rate of ongoing neurodegeneration. High CSF NFL levels are seen 
days after a bout in amateur boxing,6 with subsequent decrease during the next months, CSF 
NFL levels are highest in MS patients with an ongoing relapse,39 and high CSF NFL levels are 
associated with progression of neurodegenerative diseases.4, 9, 12, 13 Accordingly, CSF NFL levels 
are higher in the rapidly progressing neurodegenerative disease amyotrophic lateral sclerosis 
than in AD which progresses more slowly,12 and MCI patients have CSF NFL levels that are 
intermediate between those of AD patients and controls.4 Thus, CSF NFL may reflect that 
similar neurodegenerative processes are ongoing in both normal aging and diseases, and the CSF 
NFL levels may reflect the progression rate of the processes.  
 
Unexpectedly,40 in the final model, higher P-tau levels predicted lower hippocampal atrophy 
rates. One explanation for this finding may be that our study could have excluded individuals 
with high CSF P-tau levels and high hippocampal atrophy rates, as they are more likely to have 
dementia or cognitive impairment. Therefore, this result should be interpreted with caution. Also, 
it must be noted that P-tau was not significantly related to atrophy when no covariates were 
included in the model, nor in GAMM, and we can thus not exclude the possibility that the 
unexpected relationship with hippocampal atrophy is due to shared variance with the other 
covariates NFL and age.  
 
The main limitation is that although the likelihood of confounding by presymptomatic AD is low, 
we cannot rule out the possibility that presymptomatic neurodegenerative pathology of other 
etiologies may in part account for some of the relationship between CSF NFL and hippocampal 
atrophy. Further, although the participants were followed for two years, we cannot be sure that 
these participants do not develop neurodegenerative diseases later.  
 
CONCLUSION 
CSF NFL predicts neurodegeneration in older adults with very low probability of AD. The 
present results suggest that factors previously shown to be important for brain degeneration in 
MCI may also impact brain changes in normal aging, demonstrating that NFL is likely to be a 
marker of AD-independent, age-expected neurodegeneration.  
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FIGURE LEGENDS 
Figure 1. Relationship between age and hippocampal volume.  
Legend: Adjusted for sex. The graph shows mean slope with 95 % confidence interval. Data 
points from participants with MRI are displayed, including within-person changes for those with 
MRI at both time points. MRI = magnetic resonance imaging. 
 
Figure 2. Relationship between age and hippocampal volume in NFL+ and NFL- participants.  
Legend: Adjusted for sex. NFL+ (> 902 pg/mL) and NFL- (≤ 902pg/mL) participants are 
defined by a median split. Estimated group slopes with 95 % confidence intervals are displayed. 
Data from participants with MRI at one or both time points are used. NFL = cerebrospinal fluid 
neurofilament light. MRI = magnetic resonance imaging. 
 
Figure 3. NFL mediates the effect of age on hippocampal atrophy rate. 
Legend: Path analyses showing that NFL mediates the effect of age on hippocampal atrophy rate. 
Standardized regression coefficients for the paths are presented; A) c = the direct association 
between age and hippocampal atrophy rate, B) a = the association between age and NFL, b = the 
association between NFL and hippocampal atrophy rate adjusted for age, and c’ the association 
between age and hippocampal atrophy rate adjusting for NFL. The regression coefficient for the 
mediation effect (c-c’ = a*b) and the % reduction of the effect of age on hippocampal atrophy 
rate are also presented. The bootstrapped 95 % confidence interval for the mediation effect was -
.24 to -.01, showing that the mediation effect is significant. NFL = cerebrospinal fluid 
neurofilament light level.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLES 
Table 1. Demographics, CSF biomarkers and hippocampal measures. 
 All participants (n=144) Participants with MRI at both 
time points and CSF NFL 
analyses (n=88) 
Age at baseline, years 73 (6), 64 to 91 
 
73 (6), 64 to 89 
Sex, male 68 (47) 43 (49) 
Education, years 14 (4), 7 to 23 15 (3), 8 to 23 
MMSE score, baseline 29 (1.2), 25 to 30 
 
29 (1.3), 25 to 30 
MMSE score, 2-year follow-
up 
29 (1.4), 21 to 30a 29 (1.2), 24 to 30 
APOE genotypeb 
 E3/E2 
 E3/E3 
 E4/E2 
 E4/E3 
 E4/E4 
 
12 (9) 
68 (53) 
1 (1) 
44 (34) 
4 (3) 
 
4 (5) 
44 (53) 
1 (1) 
31 (37) 
3 (4) 
CSF Aβ42, pg/mL 718 (208), 275 to 1179c 724 (203), 275 to 1175 
CSF P-tau, pg/mL 60 (20), 25 to 115c 61 (19), 26 to 110 
CSF NFL, pg/mL 1163 (507), 487 to 3123d 1141 (558), 510 to 3123 
Aβ42+ (< 550 pg/mL) 34 (26)c 24 (27) 
Months between MRIs - 26 (3), 19 to 35 
Hippocampal volume, 
baseline, mm3 
- 3505 (396), 2337 to 4544 
 
Hippocampal volume, 2-year 
follow up, mm3 
- 3464 (407), 2425 to 4514 
Hippocampal volume, % 
annual change  
- -.55 (1.08), -4.24 to 2.14 
 
Legend: Values are n (%) and mean (SD), range. an=115, bn=129 and n=83, respectively, 
cn=130,dn=128.  MMSE = Mini Mental Status Examination. APOE = Apolipoprotein E. CSF = 
cerebrospinal fluid. Aβ42= β-amyloid 1-42. P-tau = phosphorylated tau. NFL = neurofilament 
light. MRI = magnetic resonance imaging. 
 
Table 2. Multiple linear regression with hippocampal atrophy rate as dependent variable (full 
sample).  
Independent variables R2 B 95 % CI β P value 
Age 
NFL 
.13 -.024 
-.001 
-.064 to .016 
-.001 to -.00001 
-.14 
-.28 
.23 
.02 
Age 
NFL 
.16 -.025 
-.001 
-.064 to .015 
-.001 to -.0001 
-.14 
-.29 
.22 
.01 
Aβ42 .001 -.0002 to .002 .16 .11 
Age 
NFL 
P-tau 
.20 -.023 
-.001 
.016 
-.062 to .015 
-.001 to -.0002 
.004 to .027 
-.13 
-.34 
.27 
.23 
.003 
.009 
 
Legend: Aβ42= cerebrospinal fluid β-amyloid 1-42. P-tau = cerebrospinal fluid phosphorylated 
tau. NFL = cerebrospinal fluid neurofilament light. 
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